{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:01:06Z","timestamp":1789614066555,"version":"build-2803163510"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The circadian clock (CC) has biological and clinical implications in gliomas. Most studies focused on CC effects on the tumor microenvironment and the application of chronotherapy. The present study focused on CC gene expression patterns and intracellular oncogenic activities. Glioma gene expression data were collected from The Human Cancer Genome Atlas (TCGA) project. After applying inclusion and exclusion criteria, we selected 666 patients from TCGA-GBM and TCGA-LGG projects and included important clinicopathological variables. The entire cohort was subjected to clustering analysis and divided into CC1 and CC2 subtypes based on statistical, biological, and clinical criteria. CC2 gliomas showed higher expression of BMAL1 and CRY1 and lower expression of CRY2 and PER2 (adjusted P\u2009&amp;lt;\u2009.001). CC2 gliomas had q higher activity of cell proliferation, metabolic reprogramming, angiogenesis, hypoxia, and many oncogenic signals (P\u2009&amp;lt;\u2009.001). The CC2 subtype contained a higher proportion of glioblastomas (P\u2009&amp;lt;\u2009.001) and had a worse prognosis (P\u2009&amp;lt;\u2009.001). Stratified Kaplan\u2013Meier and multivariable Cox analyses illustrated that the CC subtype is an independent prognostic factor to clinicopathological characteristics (P\u2009&amp;lt;\u2009.001), genetic aberrations (P\u2009=\u2009.006), and biological processes (P\u2009&amp;lt;\u2009.001). Thus, this study shows statistical evidence of CC subtypes and their biological, and clinicopathological significance in adult gliomas.<\/jats:p>","DOI":"10.1093\/jnen\/nlae055","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T08:23:09Z","timestamp":1719649389000},"page":"736-744","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive analysis of distinct circadian clock subtypes of adult diffuse glioma and their associations with clinicopathological, genetic, and epigenetic profiles"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-0888","authenticated-orcid":false,"given":"Minh-Khang","family":"Le","sequence":"first","affiliation":[{"name":"Department of Human Pathology, University of Yamanashi , Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Quoc Vuong","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Yamanashi , Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc-Tan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Yamanashi , Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy-An","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Yamanashi , Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhito","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Yamanashi , Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2268-0302","authenticated-orcid":false,"given":"Tetsuo","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, University of Yamanashi , Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"1","key":"2024082007511526500_nlae055-B1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13073-019-0704-0","article-title":"Genomics of circadian rhythms in health and disease","volume":"11","author":"Rijo-Ferreira","year":"2019","journal-title":"Genome Med"},{"issue":"10","key":"2024082007511526500_nlae055-B2","doi-asserted-by":"crossref","first-page":"R432","DOI":"10.1016\/j.cub.2016.04.011","article-title":"The circadian clock and human health","volume":"26","author":"Roenneberg","year":"2016","journal-title":"Curr Biol"},{"issue":"1","key":"2024082007511526500_nlae055-B3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bj.2018.02.003","article-title":"The discoveries of molecular mechanisms for the circadian rhythm: the 2017 Nobel Prize in Physiology or Medicine","volume":"41","author":"Huang","year":"2018","journal-title":"Biomed J"},{"issue":"3","key":"2024082007511526500_nlae055-B4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrg.2016.150","article-title":"Transcriptional architecture of the mammalian circadian clock","volume":"18","author":"Takahashi","year":"2017","journal-title":"Nat Rev Genet"},{"issue":"8","key":"2024082007511526500_nlae055-B5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","article-title":"Interplay between circadian clock and cancer: new frontiers for cancer treatment","volume":"5","author":"Sulli","year":"2019","journal-title":"Trends Cancer"},{"key":"2024082007511526500_nlae055-B6","doi-asserted-by":"crossref","first-page":"592080","DOI":"10.3389\/fimmu.2020.592080","article-title":"TGF-\u03b2 signaling promotes glioma progression through stabilizing Sox9","volume":"11","author":"Chao","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2024082007511526500_nlae055-B7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13046-019-1269-x","article-title":"MET in glioma: signaling pathways and targeted therapies","volume":"38","author":"Cheng","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2024082007511526500_nlae055-B8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s11481-012-9359-y","article-title":"Wnt\/beta-catenin signaling in glioma","volume":"7","author":"Zhang","year":"2012","journal-title":"J Neuroimmune Pharmacol"},{"key":"2024082007511526500_nlae055-B9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-030-30651-9_10","article-title":"STAT signaling in glioma cells","volume":"1202","author":"Swiatek-Machado","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2024082007511526500_nlae055-B10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1566524033361609","article-title":"Signaling pathways regulating gliomagenesis","volume":"3","author":"Konopka","year":"2003","journal-title":"Curr Mol Med"},{"key":"2024082007511526500_nlae055-B11","doi-asserted-by":"crossref","first-page":"9774879","DOI":"10.1155\/2022\/9774879","article-title":"Circadian clock genes act as diagnostic and prognostic biomarkers of glioma: clinic implications for chronotherapy","volume":"2022","author":"Chai","year":"2022","journal-title":"Biomed Res Int"},{"issue":"11","key":"2024082007511526500_nlae055-B12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-19-0215","article-title":"Targeting glioblastoma stem cells through disruption of the circadian clock","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov"},{"issue":"11","key":"2024082007511526500_nlae055-B13","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.3390\/cancers13112756","article-title":"Association of circadian clock gene expression with glioma tumor microenvironment and patient survival","volume":"13","author":"De La Cruz Minyety","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2024082007511526500_nlae055-B14","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.febslet.2013.06.018","article-title":"Circadian gene clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124","volume":"587","author":"Li","year":"2013","journal-title":"FEBS Lett"},{"issue":"9","key":"2024082007511526500_nlae055-B15","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.7150\/thno.43834","article-title":"Targeting REV-ERB\u03b1 for therapeutic purposes: promises and challenges","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"issue":"6886","key":"2024082007511526500_nlae055-B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/417329a","article-title":"Circadian rhythms from flies to human","volume":"417","author":"Panda","year":"2002","journal-title":"Nature"},{"issue":"6909","key":"2024082007511526500_nlae055-B17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature01123","article-title":"Dec1 and Dec2 are regulators of the mammalian molecular clock","volume":"419","author":"Honma","year":"2002","journal-title":"Nature"},{"issue":"5","key":"2024082007511526500_nlae055-B18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nrc1072","article-title":"The circadian clock: pacemaker and tumour suppressor","volume":"3","author":"Fu","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2024082007511526500_nlae055-B19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0092-8674(02)01225-4","article-title":"A web of circadian pacemakers","volume":"111","author":"Schibler","year":"2002","journal-title":"Cell"},{"issue":"10","key":"2024082007511526500_nlae055-B20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrg2430","article-title":"The genetics of mammalian circadian order and disorder: implications for physiology and disease","volume":"9","author":"Takahashi","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"7","key":"2024082007511526500_nlae055-B21","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/jnen\/nlad037","article-title":"NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas","volume":"82","author":"Le","year":"2023","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"2024082007511526500_nlae055-B22","doi-asserted-by":"crossref","first-page":"e0290542","DOI":"10.1371\/journal.pone.0290542","article-title":"Molecular and clinicopathological implications of PRAME expression in adult glioma","volume":"18","author":"Le","year":"2023","journal-title":"PLoS One"},{"key":"2024082007511526500_nlae055-B23","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7269","key":"2024082007511526500_nlae055-B24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"2024082007511526500_nlae055-B25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2024082007511526500_nlae055-B26","author":"Bedre","year":"2020"},{"issue":"1","key":"2024082007511526500_nlae055-B27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-021-01085-7","article-title":"DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas","volume":"13","author":"Ferreyra Vega","year":"2021","journal-title":"Clin Epigenetics"},{"key":"2024082007511526500_nlae055-B28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fonc.2020.00199","article-title":"Insights about circadian clock and molecular pathogenesis in gliomas","volume":"10","author":"Arafa","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"2024082007511526500_nlae055-B29","doi-asserted-by":"crossref","first-page":"e12988","DOI":"10.1111\/cpr.12988","article-title":"Circadian clock genes promote glioma progression by affecting tumour immune infiltration and tumour cell proliferation","volume":"54","author":"Wang","year":"2021","journal-title":"Cell Prolif"},{"issue":"3","key":"2024082007511526500_nlae055-B30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/2159-8290.CD-19-0400","article-title":"Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment","volume":"10","author":"Chen","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"2024082007511526500_nlae055-B31","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/2326-6066.CIR-21-0559","article-title":"Circadian regulator CLOCK drives immunosuppression in glioblastoma","volume":"10","author":"Xuan","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2024082007511526500_nlae055-B32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12885-017-3896-y","article-title":"Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness","volume":"18","author":"Goldsmith","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"2024082007511526500_nlae055-B33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"2024082007511526500_nlae055-B34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"2024082007511526500_nlae055-B35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1521-1878(199903)21:3<221::AID-BIES6>3.0.CO;2-J","article-title":"E2F target genes and cell-cycle checkpoint control","volume":"21","author":"Lavia","year":"1999","journal-title":"Bioessays"},{"key":"2024082007511526500_nlae055-B36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"2024082007511526500_nlae055-B37","doi-asserted-by":"crossref","first-page":"a026070","DOI":"10.1101\/cshperspect.a026070","article-title":"p53 in the DNA-damage-repair process","volume":"6","author":"Williams","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2024082007511526500_nlae055-B38","doi-asserted-by":"crossref","first-page":"103135","DOI":"10.1016\/j.dnarep.2021.103135","article-title":"Modulation of immune responses by DNA damage signaling","volume":"104","author":"Uchihara","year":"2021","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"2024082007511526500_nlae055-B39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/15384101.2018.1558638","article-title":"The positive circadian regulators CLOCK and BMAL1 control G2\/M cell cycle transition through cyclin B1","volume":"18","author":"Farshadi","year":"2019","journal-title":"Cell Cycle"},{"key":"2024082007511526500_nlae055-B40","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1111\/cas.13714","article-title":"MicroRNAs as potential biomarkers for the diagnosis of glioma: a systematic review and meta-analysis","volume":"109","author":"Zhou","year":"2018","journal-title":"Cancer Sci"},{"key":"2024082007511526500_nlae055-B41","doi-asserted-by":"crossref","first-page":"4085039","DOI":"10.1155\/2022\/4085039","article-title":"The expression profile of miRNA in glioma and the role of miR-339-5p in glioma","volume":"2022","author":"Lin","year":"2022","journal-title":"Biomed Res Int"},{"key":"2024082007511526500_nlae055-B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2021.11.016","article-title":"miRNA-338-3p inhibits glioma cell proliferation and progression by targeting MYT1L","volume":"179","author":"Yu","year":"2022","journal-title":"Brain Res Bull"},{"issue":"5 Pt A","key":"2024082007511526500_nlae055-B43","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbadis.2018.02.022","article-title":"PVT1 regulates the malignant behaviors of human glioma cells by targeting miR-190a-5p and miR-488-3p","volume":"1864","author":"Xue","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"12","key":"2024082007511526500_nlae055-B44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/WNR.0000000000000410","article-title":"MiR-27a regulates Wnt\/beta-catenin signaling through targeting SFRP1 in glioma","volume":"26","author":"Wang","year":"2015","journal-title":"Neuroreport"},{"key":"2024082007511526500_nlae055-B45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/tox.22873","article-title":"BRD4 promotes glioma cell stemness via enhancing miR-142-5p-mediated activation of Wnt\/\u03b2-catenin signaling","volume":"35","author":"Wang","year":"2020","journal-title":"Environ Toxicol"},{"key":"2024082007511526500_nlae055-B46","first-page":"4943","article-title":"Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma","volume":"8","author":"Pang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"2024082007511526500_nlae055-B47","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2024082007511526500_nlae055-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22020587","article-title":"Updated insights on EGFR signaling pathways in glioma","volume":"22","author":"Oprita","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2024082007511526500_nlae055-B49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00018-017-2714-7","article-title":"Signaling pathways and mesenchymal transition in pediatric high-grade glioma","volume":"75","author":"Meel","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2024082007511526500_nlae055-B50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/neup.12535","article-title":"Metabolic reprogramming in the pathogenesis of glioma: update","volume":"39","author":"Masui","year":"2019","journal-title":"Neuropathology"},{"key":"2024082007511526500_nlae055-B51","doi-asserted-by":"crossref","first-page":"e12929","DOI":"10.1111\/cpr.12929","article-title":"Activation of nuclear factor-\u03baB in the angiogenesis of glioma: insights into the associated molecular mechanisms and targeted therapies","volume":"54","author":"Tu","year":"2021","journal-title":"Cell Prolif"},{"issue":"1","key":"2024082007511526500_nlae055-B52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12883-020-01888-w","article-title":"Establishment of age group classification for risk stratification in glioma patients","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Neurol"},{"key":"2024082007511526500_nlae055-B53","doi-asserted-by":"crossref","first-page":"e2203936119","DOI":"10.1073\/pnas.2203936119","article-title":"CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy","volume":"119","author":"Miller","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6098","key":"2024082007511526500_nlae055-B54","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.1223710","article-title":"Identification of small molecule activators of cryptochrome","volume":"337","author":"Hirota","year":"2012","journal-title":"Science"},{"issue":"7803","key":"2024082007511526500_nlae055-B55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41586-020-2188-x","article-title":"A reference map of the human binary protein interactome","volume":"580","author":"Luck","year":"2020","journal-title":"Nature"}],"container-title":["Journal of Neuropathology &amp; Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/83\/9\/736\/58813127\/nlae055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/83\/9\/736\/58813127\/nlae055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T05:54:58Z","timestamp":1724133298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnen\/article\/83\/9\/736\/7706268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,4]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnen\/nlae055","relation":{},"ISSN":["0022-3069","1554-6578"],"issn-type":[{"value":"0022-3069","type":"print"},{"value":"1554-6578","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,4]]}}}